GLPI-103 — Regulatory Dossier: Reader's Guide

🧪

Mock / simulation document

This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.

📚

What this is

A beginner-friendly walk-through of a complete, submission-shaped regulatory dossier for a virtual drug — GLPI-103, a GLP-1 / Apelin (APJ) dual agonist for type 2 diabetes. Each linked article opens with a plain-language guide (what the document is, why it is required, how it is produced, and what standard governs it), adds short memo bubbles at the key points, and then shows the document itself. Every clinical number comes from one simulated Phase 3 trial; the nonclinical (Module 4) and manufacturing (Module 3) sections are deep-knowledge mock, labelled [MOCK] where they stand in for real data.

🗺️

How a submission is organized (the CTD)

Marketing applications worldwide share the ICH Common Technical Document (CTD), a five-module structure. Module 1 is region-specific admin and labeling; Module 2 is the high-level summaries a reviewer reads first; Module 3 is quality / manufacturing (CMC); Module 4 is the animal (nonclinical) studies; Module 5 is the human clinical studies and data. The Trial Master File, program-management, and quality documents are the operational records that stand behind the trial.

Every document, explained

Module 1 — Regional & Administrative

Module 1 — Administrative Documents & Certifications Index — GLPI-103 — The index and cover layer of CTD Module 1 — the region-specific administrative forms, certifications, and references that sit in front of the scientific dossier.
US NDA — Form FDA 356h, Cover Letter & Certifications — GLPI-103 — The executed-style US marketing-application forms: Form FDA 356h, the submission cover letter, and the financial-disclosure, debarment, environmental, patent, and user-fee certifications.
EU MAA — Application Form (eAF) & Cover Letter — GLPI-103 — The executed-style EU centralised Marketing Authorisation Application form (eAF) and cover letter.
MFDS 품목허가신청서 & 표지서한 — GLPI-103 — The executed-style Korean marketing-authorisation application form (품목허가신청서) and cover letter (표지서한).
US Investigational New Drug (IND) Application — Summary — GLPI-103 — A summary of the US Investigational New Drug (IND) application — the package a sponsor files with the FDA before dosing humans in the US.
Module 1 (US) — Administrative & US Prescribing Information — GLPI-103 — The US administrative content plus the US Prescribing Information (USPI) — the FDA-format drug label.
FDA Risk Management & REMS Assessment — GLPI-103 — The FDA risk-management assessment and REMS (Risk Evaluation and Mitigation Strategy) analysis — whether extra safety controls beyond labeling are needed.
EU Investigational Medicinal Product Dossier (IMPD) — Summary — GLPI-103 — A summary of the EU Investigational Medicinal Product Dossier (IMPD) — the European counterpart to the information supporting a clinical-trial application.
Module 1 (EU) — Administrative & Summary of Product Characteristics — GLPI-103 — The EU administrative content plus the Summary of Product Characteristics (SmPC) — the European drug label.
EU Risk Management Plan (EU-RMP) — GLPI-103 — The EU Risk Management Plan — a structured description of a medicine's safety profile and how its risks will be characterized and minimized.
임상시험계획승인신청(IND) 요약 — GLPI-103 (MFDS) — A summary of the Korean clinical-trial application (IND) filed with the MFDS (Ministry of Food and Drug Safety).
Module 1 (Korea) — 행정정보 및 허가사항(라벨) — GLPI-103 — The Korean administrative content and the Korean product label (허가사항).
MFDS Risk Management Plan (위해성 관리 계획, RMP) — GLPI-103 — The Korean Risk Management Plan (위해성 관리 계획) filed with the MFDS.
Pediatric Plan (US PSP / EU PIP) — GLPI-103 — The pediatric development plan — the US Pediatric Study Plan (PSP) and the EU Paediatric Investigation Plan (PIP).
Pre-IND Meeting Briefing Document — GLPI-103 — The briefing book for a Pre-IND meeting with the FDA — the questions and supporting summary a sponsor sends before that meeting.
End-of-Phase-2 (EOP2) Meeting Briefing Document — GLPI-103 — The briefing book for the End-of-Phase-2 (EOP2) meeting with the FDA.
Pre-NDA Meeting Briefing Document — GLPI-103 — The briefing book for the Pre-NDA/Pre-BLA meeting with the FDA.
Expedited Program Designation Requests — GLPI-103 — Requests for expedited-program designations (e.g., Fast Track, Breakthrough Therapy, Priority Review) and their rationale.
Development Safety Update Report (DSUR) — GLPI-103 — The Development Safety Update Report — the annual safety report while a drug is still in clinical development.
Periodic Benefit-Risk Evaluation Report (PBRER/PSUR) — GLPI-103 — The Periodic Benefit-Risk Evaluation Report (PBRER/PSUR) — the periodic post-approval safety and benefit-risk review.
Signal Management Plan — GLPI-103 — The signal-management plan — how potential new safety signals are detected, prioritized, evaluated, and acted on.

Module 2 — CTD Summaries & Overviews

Module 2.1 — CTD Table of Contents — The CTD table of contents for the whole submission — the map of Modules 2 through 5.
Module 2.2 — Introduction — A one-page introduction to the product: its pharmacologic class, proposed indication, and dosage form.
Module 2.3 — Quality Overall Summary (QOS) — GLPI-103 — The Quality Overall Summary — the high-level synopsis of the chemistry, manufacturing, and controls (Module 3).
Module 2.4 — Nonclinical Overview — The Nonclinical Overview — an integrated, interpretive appraisal of the animal pharmacology, PK, and toxicology.
Module 2.5 — Clinical Overview — The Clinical Overview — a short, interpretive appraisal of the clinical evidence written for regulators.
Module 2.5.6 — Benefits and Risks Conclusions — The structured Benefits and Risks conclusions section of the Clinical Overview.
Module 2.6 — Nonclinical Written & Tabulated Summaries — The Nonclinical Written and Tabulated Summaries — the factual condensation of the Module 4 animal studies.
Module 2.7.1 — Summary of Biopharmaceutic Studies & Analytical Methods — The Summary of Biopharmaceutic Studies and associated analytical methods (bioavailability, bioequivalence, formulation).
Module 2.7.2 — Summary of Clinical Pharmacology Studies — The Summary of Clinical Pharmacology — human PK/PD, dose-exposure-response, and special-population and QT findings.
Module 2.7.3 — Summary of Clinical Efficacy — The Summary of Clinical Efficacy — the integrated, cross-study account of how well the drug works.
Module 2.7.4 — Summary of Clinical Safety — The Summary of Clinical Safety — the integrated safety picture across exposure, adverse events, special-interest events, deaths, and labs.
Module 2.7.5 — Literature References — The list of literature references cited across the clinical summaries.
Module 2.7.6 — Synopses of Individual Studies — Structured synopses of each individual clinical study in the program.

Module 3 — Quality (CMC)

Module 3 — Quality (CMC) — GLPI-103 — The Module 3 (Quality / CMC) index and overview tying together the drug substance, drug product, and supporting quality sections.
Module 3.2.S — Drug Substance (Full) — GLPI-103 — Module 3.2.S — the full drug substance (active ingredient) section: manufacture, characterization, control, and stability.
Module 3.2.P — Drug Product (Full) — GLPI-103 — Module 3.2.P — the full drug product (finished dosage form) section: formulation, manufacture, control, and stability.
Quality Target Product Profile (QTPP) & Critical Quality Attributes (CQA) — GLPI-103 — The Quality Target Product Profile (QTPP) and Critical Quality Attributes (CQAs).
Control Strategy — GLPI-103 — The control strategy — the planned set of controls that assure the product consistently meets its quality attributes.
Process Development & Validation Summary — GLPI-103 — The process development and validation summary — evidence the commercial manufacturing process reliably produces conforming product.
Analytical Methods & Validation Summary — GLPI-103 — The analytical methods and their validation — the test methods used to measure identity, purity, potency, and impurities.
Stability Summary — GLPI-103 — The stability summary — how the substance and product change over time and the resulting shelf life and storage conditions.
Module 3.2.A Appendices & 3.2.R Regional Information — GLPI-103 — Module 3.2.A appendices (e.g., facilities, adventitious-agent safety) and 3.2.R regional quality information.

Module 4 — Nonclinical (Animal) Study Reports

Module 4 — Nonclinical Study Reports (Index & Stubs) — GLPI-103 — The Module 4 index and study-report stubs — the map of the animal pharmacology, PK, and toxicology reports.
Module 4.2.1 — Pharmacology Study Reports — GLPI-103 — Module 4.2.1 — the pharmacology study reports: primary (does it work), secondary, and safety pharmacology.
Module 4.2.2 — Pharmacokinetic Study Reports — GLPI-103 — Module 4.2.2 — the nonclinical pharmacokinetic study reports (absorption, distribution, metabolism, excretion, and toxicokinetics).
Module 4.2.3 — Toxicology Study Reports — GLPI-103 — Module 4.2.3 — the toxicology study reports: single- and repeat-dose toxicity, genotoxicity, carcinogenicity, reproductive, and other studies.
Nonclinical Data Reviewer's Guide (nSDRG) — SEND — GLPI-103 — The Nonclinical Data Reviewer's Guide (nSDRG) for the SEND datasets — the animal-study equivalent of the clinical reviewer's guides.

Module 5 — Clinical Study Reports & Data

Clinical Study Protocol — GLPI103-301 — The full Phase 3 clinical study protocol — the design, eligibility, treatments, endpoints, estimands, and visit schedule, fixed before any data exist.
Statistical Analysis Plan — GLPI103-301 — The Statistical Analysis Plan — exactly how the trial will be analysed, locked before the blind is broken.
Statistical Analysis Report — GLPI103-301 — The Statistical Analysis Report — the narrative synthesis of every statistical analysis actually run, with the methods and results laid out end to end.
ADaM Dataset Specification — GLPI103-301 — The ADaM dataset specification — the variable-by-variable definition of the analysis datasets (e.g., ADSL, ADLB).
Tables, Listings & Figures (TLF) Shells — GLPI103-301 — The Tables, Listings, and Figures (TLF) shells — the empty, pre-specified templates of every output the report will contain.
Clinical Study Report — GLPI103-301 — The full Clinical Study Report for the pivotal Phase 3 study — the definitive account of disposition, efficacy, and safety.
Patient Narratives (CSR Appendix 16.3) — GLPI103-301 — The written patient narratives for every death, serious adverse event, and adverse-event discontinuation in the pivotal trial — the ICH E3 §16.3 appendix to the CSR.
Clinical Study Report (Abbreviated) — GLPI103-101 (FIH / SAD) — An abbreviated clinical study report for the first-in-human single-ascending-dose (SAD) study.
Clinical Study Report (Abbreviated) — GLPI103-102 (MAD / early efficacy) — An abbreviated clinical study report for the multiple-ascending-dose (MAD) study with early efficacy signals.
Clinical Study Report (Abbreviated) — GLPI103-201 (Phase 2 PoC / dose-finding) — An abbreviated clinical study report for the Phase 2 proof-of-concept / dose-finding study.
Biopharmaceutic Study Reports (Module 5.3.1) — GLPI-103 — The biopharmaceutic study reports — absolute/relative bioavailability, food and dosing-condition effects, and the bridge between the IV and oral forms.
Human Pharmacokinetic Study Reports (Module 5.3.3) — GLPI-103 — The human PK evidence — single/multiple-dose PK, population PK and exposure–response, and hepatic-, renal-impairment and drug–drug-interaction studies.
Human Pharmacodynamic & Cardiac-Safety (QT) Study Reports (Module 5.3.4) — GLPI-103 — The human PD (biomarker) evidence and the ICH E14 cardiac-safety (thorough-QT / concentration–QTc) assessment.

Trial Master File — how the trial is run

Informed Consent Form (ICF) — GLPI103-301 (template) — The Informed Consent Form template — the document a subject reads and signs before joining the trial.
Data Management Plan (DMP) — GLPI103-301 — The Data Management Plan — how trial data are collected, cleaned, coded, and locked.
Clinical Monitoring Plan (CMP) — GLPI103-301 — The Clinical Monitoring Plan — how sites are monitored to protect subjects and data quality.
Data Safety Monitoring Board (DSMB) Charter — GLPI103-301 — The Data Safety Monitoring Board charter — the mandate and procedures of the independent board overseeing subject safety.
Randomization & IWRS Specification + UAT — GLPI103-301 — The randomization and IWRS specification (plus user-acceptance testing) — how subjects are assigned to treatments and how the system is validated.
Safety Management Plan (SMP) — GLPI103-301 — The Safety Management Plan — how adverse events are collected, assessed, and reported during the trial.
DSMB Meeting Minutes (Summary) — GLPI103-301 — Summary minutes of a DSMB meeting.
Pharmacy / IMP Manual — GLPI103-301 — The Pharmacy / Investigational Medicinal Product manual — how the study drug is received, stored, prepared, and dispensed at sites.
Central Laboratory Manual — GLPI103-301 — The central laboratory manual — how samples are collected, handled, shipped, and analysed.
Clinical Trial Agreement (CTA) & IRB/IEC Approval Tracker — GLPI103-301 — The Clinical Trial Agreement (CTA) and the IRB/IEC approval tracker.

Program Management

Project Charter — GLPI-103 Development Program — The project charter — the founding document authorizing the development program and defining its objectives, scope, and governance.
Integrated Program Timeline & Milestones — GLPI-103 — The integrated program timeline and milestones — the schedule from nonclinical through submission.
Clinical Program Budget & Cost Model — GLPI-103 — The clinical program budget and cost model.
Project Risk Register — GLPI-103 Development Program — The project risk register — the catalogue of program risks with their likelihood, impact, and mitigations.
Governance & RACI / Phase-Gate Criteria — GLPI-103 — The governance model, RACI matrix, and phase-gate criteria.
Resource & Vendor (CRO) Management Plan — GLPI-103 — The resource and vendor / CRO management plan — how outsourced work is selected and overseen.
Clinical Development Plan (CDP) — GLPI-103 — The Clinical Development Plan — the strategic roadmap of studies from first-in-human to registration and beyond.

Quality

Quality Management Plan (QMP) — GLPI103-301 Program — The Quality Management Plan — how quality is designed into and assured across the program.
Protocol Deviation Log — GLPI103-301 — The protocol deviation log — the record of departures from the protocol and their significance.
Issue & CAPA Log — GLPI-103 Program — The issue and CAPA (Corrective and Preventive Action) log.
Decision & Action-Item Log — GLPI-103 Program — The decision and action-item log — the record of key program decisions and their rationale.

Portfolio project. The drug, sponsor, and data are fictional; the standards, methods, and document structure are real.

(페이지 작성중; Page under construction) 방명록을 남겨주세요! Please leave a comment in my guestbook!